Business Context and Reporting Period
This Form 8-K, filed on February 10, 2025, reports on events occurring on February 4, 2025, regarding PowerUp Acquisition Corp. (the "Company"). The Company held an extraordinary general meeting to approve a business combination with Aspire Biopharma, Inc. ("Aspire"). Upon consummation, the Company will be domesticated from the Cayman Islands to Delaware and renamed "Aspire Biopharma Holdings, Inc." ("New Aspire").
Key Financial Metrics and Transaction Details
The filing focuses on corporate governance and transaction mechanics rather than operating financials. Key financial data points include:
- Share Redemptions: 507,631 Class A ordinary shares were validly elected for redemption.
- Redemption Value: Approximately $5,802,222.33 will be removed from the trust account to pay redeeming shareholders.
- Price Per Share: The redemption price was $11.43 per share.
- Outstanding Shares (Record Date): 7,756,144 Class A ordinary shares were issued and outstanding as of December 24, 2024.
- Attendance: 7,194,175.49504 shares (92.8%) were present or represented by proxy.
The filing does not provide revenue, profit, cash flow, margins, or debt figures for Aspire or the combined entity.
Material Changes and Voting Results
Shareholders overwhelmingly approved all proposals required to consummate the transaction. The material changes include the merger of PowerUp Merger Sub II, Inc. with Aspire, the domestication of the Company to Delaware, and the change of name to Aspire Biopharma Holdings, Inc.
Voting Summary:
- Business Combination Proposal: Approved (7,188,887 For; 5,288 Against).
- Domestication Proposal: Approved (7,188,757 For; 5,288 Against).
- Organizational Documents Proposal: Approved (7,188,757 For; 5,318 Against).
- Advisory Governance Proposals (4A-4H): All approved with minimal opposition (ranging from 5,288 to 5,418 votes against).
- Nasdaq Listing Proposal: Approved (7,188,887 For; 5,288 Against).
- Omnibus Incentive Plan: Approved (7,188,787 For; 5,288 Against).
- Election of Directors: All seven nominees (Kraig Higginson, Michael Howe, Gary Stein, Barbara Sher, Edward Kimball, Surendra Ajjarapu, Donald G. Fell) were elected.
Outlook, Risks, and Unusual Items
Outlook and Next Steps: The Business Combination is expected to be consummated prior to February 17, 2025, subject to closing conditions. Post-combination, New Aspire common stock and warrants are expected to trade on Nasdaq under the symbols "ASBP" and "ASBPW," respectively.
Risks and Contingencies: The filing includes extensive forward-looking statements warning of risks including:
- Failure to complete the combination in a timely manner or at all.
- Redemptions exceeding anticipated levels.
- Failure to meet Nasdaq initial listing standards.
- Disruption of Aspire's current operations and business relationships.
- Need to raise additional capital to execute business plans.
- Regulatory, legal, and intellectual property risks.
Investor Verification Checklist
- Verify the final closing date of the Business Combination (expected before February 17, 2025).
- Confirm the ticker symbol change from PWUP/PWUPW to ASBP/ASBPW on Nasdaq.
- Review the Proxy Statement/Prospectus (File No. 333-281991) for detailed financial projections and risk factors not included in this 8-K.
- Monitor for any updates regarding the satisfaction of closing conditions or regulatory approvals.
- Check the final pro forma capital structure and cash position post-redemption.